Moderna ( MRNA ), racing to develop a vaccine for Covid-19, has lost a key patent decision, one that could delay the company's progress or force it to hand over a cut of profits, STAT reports. The U.S. Patent and Trademark Office denied Moderna's claim that a patent held by a rival company was invalid. The patent, which covers technology used to deliver messenger RNA treatments, is held by the Canadian firm Arbutus.